Previously, decline in ARSB was implicated in the response to hypoxia in human bronchial epithelial cells74 and in failure of patients with moderate COPD to respond to oxygen therapy.75 These findings provide additional evidence that decline in ARSB contributes to refractory clinical response in SARS-CoV- 2 infection. The gene discussed is ARSB; the disease is chronic obstructive pulmonary disease.